Manufacturer record
Rescures LIfe Sciences Ltd. 131-132 EPIP Phase-1: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Rescures LIfe Sciences Ltd. 131-132 EPIP Phase-1 (Himachal Pradesh) was declared Not of Standard Quality in November 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: RG24129T, Sodium Valproate Tablets IP 300 mg (exp Feb 2026). RDTL, Guwahati (CDSCO lab) found it not of standard quality: The sample is not of standard quality for the reason stated under "Description" of the tablets. Listed in the November 2025 alert.
Records by type
1 record linked to Rescures LIfe Sciences Ltd. 131-132 EPIP Phase-1 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Sodium Valproate Tablets IP 300 mg | Batch RG24129TMfg Mar 2024 · Exp Feb 2026 | The sample is not of standard quality for the reason stated under "Description" of the tablets.Description | RDTL, GuwahatiCDSCO lab | Nov 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.